B · Normal
[Merck’s Phase III clinical trial reaches the primary endpoint of overall survival] On November 20, Merck announced that the Phase III TroFuse-015 trial evaluating the use of the investigational drug sacituzumab tirumotecan (sac-TMT) in the third-line and later-line treatment of locally advanced unresectable or metastatic gastroesophageal adenocarcinoma has achieved the primary endpoint of overall survival (OS). Trial results showed that sac-TMT significantly improved patient overall survival compared with physician-selected treatment options. This is the first TROP2-targeted antibody drug conjugate (ADC) proven to improve overall survival through global phase III clinical trials in this type of patients. However, the drug did not meet the secondary endpoint of progression-free survival (PFS), which was reviewed by a blinded independent center. A total of 473 patients were included in the trial, and relevant data will be announced at subsequent medical conferences and submitted to regulatory agencies.
Comments